Table 1.
Patient demographics and lesion characteristics
| All | Pseudoprogression | Progression | |
|---|---|---|---|
| Patients, n | 44 | 8 | 36 |
| Median age (range) | 64 (32–86) | 52 (38–67) | 66 (32–86) |
| Women, n (%) | 15 (34%) | 4 (50%) | 11 (31%) |
| Immunotherapy: n (%) | |||
| Ipilimumab monotherapy | 28 (64%) | 4 (50%) | 24 (67%) |
| Pembrolizumab monotherapy | 9 (20%) | 2 (25%) | 9 (19%) |
| Nivolumab monotherapy | 3 (7%) | 1 (13%) | 2 (6%) |
| Other | 4 (9%) | 1 (13%) | 3 (8%) |
| Median immunotherapy duration, weeks (range) | 9 (0–138) | 9 (4–138) | 9 (0–67) |
| Lesions, n | 64 | 9 | 55 |
| Median # per patient, (range) | 1 (1–5) | 1 (1–2) | 1 (1–5) |
| Tissue diagnosis, n (%) | 14 (22%) | 1 (11%) | 13 (24%) |
| New lesions, n (%) | 20 (31%) | 1 (11%) | 19 (35%) |
| Previously irradiated, n (%) | 20 (31%) | 8 (89%) | 11 (20%) |
| Stereotactic radiosurgery | 14 | 7 | 7 |
| Whole brain radiotherapy | 5 | 0 | 5 |
| Hypofractionated radiation | 1 | 1 | 0 |
| Median days from radiation (range) | 65 (12–826) | 121 (38–826) | 32 (12–89) |
| Median days from immunotherapy (range) | 49 (5–762) | 55 (37–361) | 48 (5–762) |
| Hemorrhagic, n (%) | 52 (81%) | 8 (89%) | 44 (80%) |